<DOC>
	<DOCNO>NCT00130975</DOCNO>
	<brief_summary>The purpose study test hypothesis treatment angiotensin II type 1 receptor antagonist candesartan may reduce recurrence rate atrial fibrillation electrical cardioversion .</brief_summary>
	<brief_title>Candesartan Prevention Relapsing Atrial Fibrillation</brief_title>
	<detailed_description>Background : The effective procedure restore sinus rhythm patient persistent atrial fibrillation ( AF ) electrical cardioversion , AF recur 60-80 % patient first year . AF associate electrical anatomical remodelling atrium , angiotensin II involve remodelling process . Studies indicate angiotensin II type 1 receptor antagonist candesartan may counteract electrical anatomical remodelling induce AF . The investigator therefore hypothesised treatment candesartan may reduce recurrence rate AF electrical cardioversion . Study design : 171 patient persistent AF schedule electrical cardioversion randomise double blind , placebo-controlled study . The patient receive tablet candesartan 8 mg match placebo daily 3-6 week cardioversion , candesartan 16 mg match placebo daily 6 month cardioversion . The study medication discontinue electrical cardioversion unsuccessful AF recurrence document . Primary endpoint recurrence AF . Clinical , electrocardiographic , echocardiographic biochemical marker analyse .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Patients atrial fibrillation , diagnose electrocardiographically , 48 hour duration direct current ( DC ) cardioversion plan . Patients history know hypersensitivity contraindication angiotensin II receptor blocker angiotensinconverting enzyme ( ACE ) inhibitor . Patients currently receive ACE inhibitor angiotensin II antagonist heart failure strong indication . Patients currently receive antiarrhythmic medication include sotalol . Other betablockers regard specific antiarrhythmic agent . Significant renal artery stenosis medical condition administration vasodilator contraindicate ; serum creatinine &gt; 225 micromol/L ; serum potassium &gt; 5.5 mmol/L ; serum sodium &lt; 128 mmol/L . Patients severe hepatic dysfunction . Lifelimiting disease substance abuse may affect participation . Patients unwilling participate . Patients previously undergone DC cardioversion atrial fibrillation within last month . Thyrotoxicosis . Patients systolic blood pressure &lt; 100 mm Hg . Hypertensive patient require intensified treatment prior DC cardioversion . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Atrial fibrillation .</keyword>
	<keyword>Cardioversion .</keyword>
	<keyword>Recurrence .</keyword>
	<keyword>Candesartan .</keyword>
</DOC>